Key points
- CSL enters exclusive agreement with Alentis Therapeutics
- Focus on developing lixudebart for rare kidney and liver diseases
- CSL to fund trials and share future profits with Alentis
Full summary
CSL Ltd. announced an exclusive agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class treatment for rare kidney and liver diseases. Lixudebart is being evaluated in a Phase 2 trial for ANCA-associated vasculitis and rapidly progressive glomerulonephritis (AAV-RPGN). CSL and Alentis plan to advance lixudebart for focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC). CSL will make an initial payment of US$355 million and potentially up to an additional US$1.2 billion in commercial milestone payments. CSL will also fund the completion of the ongoing Phase 2 RENAL trial and planned Phase 3 trial in AAV-RPGN, the Phase 2 trials in FSGS and PSC, and other supporting development activities.
Outlook
CSL and Alentis aim to advance lixudebart as a potential treatment for rare kidney and liver diseases, with future commercial milestones and profit-sharing agreements.